Sandrine Marlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandrine Marlin has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Françoise Denoyelle
Service d'ORL pédiatrique et de chirurgie cervico-faciale, centre de référence des malformations ORL rares, hôpital Trousseau, 26, avenue du Dr-Arnold-Netter, 75571 Paris cedex 12, France
3 shared publications - Isabelle Rouillon
Service d’Otorhinolaryngologie et de Chirurgie Cervico-Faciale, Hôpital d’Enfants Armand-Trousseau, AP-HP, Paris, France
3 shared publications Laurence Jonard
APHP, Hôpital Necker Enfants Malades, Centre de référence des surdités génétiques, Laboratoire de Génétique moléculaire
3 shared publications- Delphine Feldmann
Unité de Génétique Médicale, INSERM UMRS 587, Hôpital d'Enfants Armand-Trousseau, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
2 shared publications - Didier Lacombe
Service de Génétique Médicale CHU Bordeaux Bordeaux France
2 shared publications E.N. Garabedian
2 shared publications
Latest Publications
- 1 September 2017
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 38 (8) , 1081-1084
Noonan Syndrome: An Underestimated Cause of Severe to Profound Sensorineural Hearing Impairment. Which Clues to Suspect the Diagnosis?
To highlight Noonan syndrome as a clinically recognizable cause of severe to profound sensorineural hearing impairment. New clinical cases and review. Patients evaluated for etiological diagnosis by a medical geneticist in a reference center for hearing impairment. Five patients presenting with confirmed Noonan syndrome and profound sensorineural hearing impairment. Diagnostic and review of the literature. Five patients presented with profound sensorineural hearing impairment and molecularly confirmed Noonan syndrome. Sensorineural hearing impairment has been progressive for three patients. Cardiac echography identified pulmonary stenosis in two patients and was normal for the three other patients. Short stature was found in two patients. Mild intellectual disability was found in one patient. Inconspicuous clinical features as facial dysmorphism, cryptorchidism, or easy bruising were of peculiar interest to reach the diagnosis of Noonan syndrome. Profound sensorineural hearing impairment can be the main feature of Noonan syndrome. Associated features are highly variable; thus, detailed medical history and careful physical examination are mandatory to consider the diagnosis in case of a sensorineural hearing impairment.
- 1 September 2017
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 38 (8) , 1081-1084
Noonan Syndrome: An Underestimated Cause of Severe to Profound Sensorineural Hearing Impairment. Which Clues to Suspect the Diagnosis?
To highlight Noonan syndrome as a clinically recognizable cause of severe to profound sensorineural hearing impairment. New clinical cases and review. Patients evaluated for etiological diagnosis by a medical geneticist in a reference center for hearing impairment. Five patients presenting with confirmed Noonan syndrome and profound sensorineural hearing impairment. Diagnostic and review of the literature. Five patients presented with profound sensorineural hearing impairment and molecularly confirmed Noonan syndrome. Sensorineural hearing impairment has been progressive for three patients. Cardiac echography identified pulmonary stenosis in two patients and was normal for the three other patients. Short stature was found in two patients. Mild intellectual disability was found in one patient. Inconspicuous clinical features as facial dysmorphism, cryptorchidism, or easy bruising were of peculiar interest to reach the diagnosis of Noonan syndrome. Profound sensorineural hearing impairment can be the main feature of Noonan syndrome. Associated features are highly variable; thus, detailed medical history and careful physical examination are mandatory to consider the diagnosis in case of a sensorineural hearing impairment.
- 1 July 2013
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 68 (7) , 501-503
Congenital Cytomegalovirus Is the Second Most Frequent Cause of Bilateral Hearing Loss in Young French Children
In children with congenital cytomegalovirus (cCMV), greater than 50% of symptomatic newborns and 8.5% to 18% of asymptomatic newborns will have hearing loss, either present at birth or delayed in onset. This prospective study was undertaken to evaluate the extent of cCMV among causes of hearing loss in French children younger than 3 years and to assess their characteristics in relation to cCMV status. Children younger than 3 years with hearing loss were prospectively enrolled. Cytomegalovirus polymerase chain reaction (PCR) assays were performed on dried blood spots from these children’s Guthrie cards and considered positive when CMV presence was confirmed. Brain computed tomography (CT) or magnetic resonance imaging and temporal bone CT scans were obtained. Normal hearing, mild loss, moderate loss, severe loss, and profound loss were defined when the child was able to hear a stimulus of 0 to 20, 21 to 40, 41 to 70, 71 to 90, and 91 dB or greater, respectively. Results of genetic analysis of the connexin 26 (GJB2) and connexin 30 (GJB2) genes were recorded. The prevalence of cCMV infection was estimated together with its 95% confidence interval. Of 114 eligible children, 100 with bilateral hearing loss were enrolled at a median age of 15 months and included in the analysis. Hearing loss in the best ear was not recorded for 2 children and was mild in 1 child, moderate in 22 children, severe in 16, and profound in 59. Results of brain and temporal bone imaging were available for 77 children and genetic analysis of the GJB2 and GJB2 genes for 55 children. Cytomegalovirus PCR was positive in 8 children, and cCMV infection prevalence was 8.0% (95% confidence interval, 2.7%–13.3%). Prevalence of cCMV was 13.7% (n = 8) in the 59 children with profound bilateral hearing loss, a significant association (P = 0.02). Children with cCMV were significantly more likely to have delayed development (P = 0.027) and abnormalities on the brain CT scan (P = 0.0005). Two of the 8 children with cCMV had at least 1 other risk factor for hearing loss, including neonatal intensive care unit stays or familial history of hearing loss. None of the 8 children with cCMV were born prematurely, but 4 had a small birth weight for their gestational age, and 1 child had microcephaly. In 2 children, the diagnosis of cCMV infection had been made before inclusion in the study. For the other 6 children, the diagnosis of cCMV was made retrospectively because of the positive CMV PCR result. In 61 patients (71.8%), the origin of hearing loss was genetic. Mutations of GJB2 and/or GJB2 genes were found in 22 patients (25.9%). In 1 patient (1.2%), hearing loss was due to a mutation in the otoferlin gene. In 13 patients (15.3%), a syndromic origin included Waardenburg syndrome, Usher syndrome, Angelman disease, mucopolysaccharidosis, and another metabolic disease. In 8 patients (9.4%), a malformation was found in the temporal bone on CT scan that was considered genetic. A genetic origin also was highly probable in 10 with a history of 1 family member with hearing loss before age 40 years and consanguineous parents in 7. Prematurity was the cause of hearing loss in 6 children (7.1%). Congenital CMV was present in 8 (9.4%) of the 85 patients with a complete workup and was the second most common individual cause of bilateral hearing loss after connexin mutations. The prevalence of cCMV indicates only the proportion of cCMV among French children with bilateral hearing loss and not the prevalence of cCMV in the total population of children with hearing loss. Because universal neonatal hearing screening is underway in France, it may be possible to diagnose cCMV in infants with confirmed hearing loss and to implement early intervention with antiviral treatment.
- 1 July 2013
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 68 (7) , 501-503
Congenital Cytomegalovirus Is the Second Most Frequent Cause of Bilateral Hearing Loss in Young French Children
In children with congenital cytomegalovirus (cCMV), greater than 50% of symptomatic newborns and 8.5% to 18% of asymptomatic newborns will have hearing loss, either present at birth or delayed in onset. This prospective study was undertaken to evaluate the extent of cCMV among causes of hearing loss in French children younger than 3 years and to assess their characteristics in relation to cCMV status. Children younger than 3 years with hearing loss were prospectively enrolled. Cytomegalovirus polymerase chain reaction (PCR) assays were performed on dried blood spots from these children’s Guthrie cards and considered positive when CMV presence was confirmed. Brain computed tomography (CT) or magnetic resonance imaging and temporal bone CT scans were obtained. Normal hearing, mild loss, moderate loss, severe loss, and profound loss were defined when the child was able to hear a stimulus of 0 to 20, 21 to 40, 41 to 70, 71 to 90, and 91 dB or greater, respectively. Results of genetic analysis of the connexin 26 (GJB2) and connexin 30 (GJB2) genes were recorded. The prevalence of cCMV infection was estimated together with its 95% confidence interval. Of 114 eligible children, 100 with bilateral hearing loss were enrolled at a median age of 15 months and included in the analysis. Hearing loss in the best ear was not recorded for 2 children and was mild in 1 child, moderate in 22 children, severe in 16, and profound in 59. Results of brain and temporal bone imaging were available for 77 children and genetic analysis of the GJB2 and GJB2 genes for 55 children. Cytomegalovirus PCR was positive in 8 children, and cCMV infection prevalence was 8.0% (95% confidence interval, 2.7%–13.3%). Prevalence of cCMV was 13.7% (n = 8) in the 59 children with profound bilateral hearing loss, a significant association (P = 0.02). Children with cCMV were significantly more likely to have delayed development (P = 0.027) and abnormalities on the brain CT scan (P = 0.0005). Two of the 8 children with cCMV had at least 1 other risk factor for hearing loss, including neonatal intensive care unit stays or familial history of hearing loss. None of the 8 children with cCMV were born prematurely, but 4 had a small birth weight for their gestational age, and 1 child had microcephaly. In 2 children, the diagnosis of cCMV infection had been made before inclusion in the study. For the other 6 children, the diagnosis of cCMV was made retrospectively because of the positive CMV PCR result. In 61 patients (71.8%), the origin of hearing loss was genetic. Mutations of GJB2 and/or GJB2 genes were found in 22 patients (25.9%). In 1 patient (1.2%), hearing loss was due to a mutation in the otoferlin gene. In 13 patients (15.3%), a syndromic origin included Waardenburg syndrome, Usher syndrome, Angelman disease, mucopolysaccharidosis, and another metabolic disease. In 8 patients (9.4%), a malformation was found in the temporal bone on CT scan that was considered genetic. A genetic origin also was highly probable in 10 with a history of 1 family member with hearing loss before age 40 years and consanguineous parents in 7. Prematurity was the cause of hearing loss in 6 children (7.1%). Congenital CMV was present in 8 (9.4%) of the 85 patients with a complete workup and was the second most common individual cause of bilateral hearing loss after connexin mutations. The prevalence of cCMV indicates only the proportion of cCMV among French children with bilateral hearing loss and not the prevalence of cCMV in the total population of children with hearing loss. Because universal neonatal hearing screening is underway in France, it may be possible to diagnose cCMV in infants with confirmed hearing loss and to implement early intervention with antiviral treatment.
- 1 June 2012
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 33 (4) , 539-544
Cochlear Implantation and Congenital Deafness
Objective: To evaluate the perceptive and linguistic results in 2 predefined genetic population of children with implants. Study Design: Retrospective cohort study. Setting: Otolaryngology department of a tertiary referral hospital. Patients Among 336 children with prelingual deafness who underwent implantation in our department between 1997 and 2007, 85 with GJB2 gene-related (Cx) deafness and 30 patients with Waardenburg syndrome (WaardS) were included. Mean age at implantation was 4.7 years (range, 15 mo to 16.5 yr) in the Cx group and 4.8 years (range, 16 mo to 16 yr) in the WaardS group. The mean follow-up period was 6.5 years (range, 19 mo to 12 yr) in the Cx group and 7.1 years (range, 27 mo to 13.5 yr) in the WaardS group. More than 75% of the families in both groups scored 4 and 5 when using the Mary Pat Moeller rating (p > 0.05). A psychoneurological evaluation was performed in one third of the patients in both groups. Main Outcome Measures Patients underwent linguistic and perceptive evaluations at 12, 24, 36, and 48 months: speech perception with closed-set and open-set words, speech production (Level 1 = vocalizations to Level 5 = complex sentences), and lexical comprehension with EVIP/GaelP (Peabody Picture Vocabulary Test) tests that ranged in 5 levels (−2 SD to +2 SD). Results Score results for open-set words were 38.5%, 57.5%, 69%, and 75% in the Cx group and 30.5%, 59%, 67.5%, and 78% in the WaardS group (p > 0.05) at 12, 24, 36, and 48 months. The proportion of children in Levels 4 and 5 of speech production was 27%, 42%, 57.5%, and 58% in the Cx group and 23%, 33%, 55%, and 66% in the WaardS group (p > 0.05). Lexical result at Level −2 SD at 1 year was 90% in the Cx group and 85% in the WaardS group and that at 4 years was 70% in the Cx group and 65% in the WaardS group (p > 0.05). Conclusion Perceptive and linguistic evolutions for both populations were of good quality, but lexical evaluation showed residual language difficulties in both groups.
- 1 June 2012
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 33 (4) , 539-544
Cochlear Implantation and Congenital Deafness
Objective: To evaluate the perceptive and linguistic results in 2 predefined genetic population of children with implants. Study Design: Retrospective cohort study. Setting: Otolaryngology department of a tertiary referral hospital. Patients Among 336 children with prelingual deafness who underwent implantation in our department between 1997 and 2007, 85 with GJB2 gene-related (Cx) deafness and 30 patients with Waardenburg syndrome (WaardS) were included. Mean age at implantation was 4.7 years (range, 15 mo to 16.5 yr) in the Cx group and 4.8 years (range, 16 mo to 16 yr) in the WaardS group. The mean follow-up period was 6.5 years (range, 19 mo to 12 yr) in the Cx group and 7.1 years (range, 27 mo to 13.5 yr) in the WaardS group. More than 75% of the families in both groups scored 4 and 5 when using the Mary Pat Moeller rating (p > 0.05). A psychoneurological evaluation was performed in one third of the patients in both groups. Main Outcome Measures Patients underwent linguistic and perceptive evaluations at 12, 24, 36, and 48 months: speech perception with closed-set and open-set words, speech production (Level 1 = vocalizations to Level 5 = complex sentences), and lexical comprehension with EVIP/GaelP (Peabody Picture Vocabulary Test) tests that ranged in 5 levels (−2 SD to +2 SD). Results Score results for open-set words were 38.5%, 57.5%, 69%, and 75% in the Cx group and 30.5%, 59%, 67.5%, and 78% in the WaardS group (p > 0.05) at 12, 24, 36, and 48 months. The proportion of children in Levels 4 and 5 of speech production was 27%, 42%, 57.5%, and 58% in the Cx group and 23%, 33%, 55%, and 66% in the WaardS group (p > 0.05). Lexical result at Level −2 SD at 1 year was 90% in the Cx group and 85% in the WaardS group and that at 4 years was 70% in the Cx group and 65% in the WaardS group (p > 0.05). Conclusion Perceptive and linguistic evolutions for both populations were of good quality, but lexical evaluation showed residual language difficulties in both groups.
- Open Access
- 5 November 2011
- Published by S. Karger AG in Audiology and Neurotology Extra
- Vol. 1 (1) , 20-29
Genetic Update on Auditory Neuropathy
Auditory neuropathy (AN) is defined as a sensorineural hearing impairment (HI) characterized by preserved cochlear outer hair cell function with normal otoacoustic emissions but abnormal or absent brainstem evoked potentials. The prevalence of AN in HIs remains to be established and its pathophysiology has not been determined. Several environmental and genetic causes have been identified, but the majority of cases remain unexplained. In the last 10 years, many genes have been identified in isolated and/or syndromic HI. Some of them (OTOF, PJVK, DIAPH3, OPA1, FXN, PMP22, ERCC6, ERCC8, SLC19A2 and TIMM8A, for example) are responsible for phenotypes corresponding to the AN definition. This review will focus on isolated and syndromic forms of AN for which the causative genes have been identified.
- 5 November 2011
- Published by S. Karger AG in Audiology and Neurotology Extra
- Vol. 1 (1) , 20-29
Open AccessGenetic Update on Auditory Neuropathy
Auditory neuropathy (AN) is defined as a sensorineural hearing impairment (HI) characterized by preserved cochlear outer hair cell function with normal otoacoustic emissions but abnormal or absent brainstem evoked potentials. The prevalence of AN in HIs remains to be established and its pathophysiology has not been determined. Several environmental and genetic causes have been identified, but the majority of cases remain unexplained. In the last 10 years, many genes have been identified in isolated and/or syndromic HI. Some of them (OTOF, PJVK, DIAPH3, OPA1, FXN, PMP22, ERCC6, ERCC8, SLC19A2 and TIMM8A, for example) are responsible for phenotypes corresponding to the AN definition. This review will focus on isolated and syndromic forms of AN for which the causative genes have been identified.
- Open Access
- 11 May 2011
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 1-19
Complete exon sequencing of all known Usher syndrome genes greatly improves molecular diagnosis
Background: Usher syndrome (USH) combines sensorineural deafness with blindness. It is inherited in an autosomal recessive mode. Early diagnosis is critical for adapted educational and patient management choices, and for genetic counseling. To date, nine causative genes have been identified for the three clinical subtypes (USH1, USH2 and USH3). Current diagnostic strategies make use of a genotyping microarray that is based on the previously reported mutations. The purpose of this study was to design a more accurate molecular diagnosis tool. Methods: We sequenced the 366 coding exons and flanking regions of the nine known USH genes, in 54 USH patients (27 USH1, 21 USH2 and 6 USH3). Results: Biallelic mutations were detected in 39 patients (72%) and monoallelic mutations in an additional 10 patients (18.5%). In addition to biallelic mutations in one of the USH genes, presumably pathogenic mutations in another USH gene were detected in seven patients (13%), and another patient carried monoallelic mutations in three different USH genes. Notably, none of the USH3 patients carried detectable mutations in the only known USH3 gene, whereas they all carried mutations in USH2 genes. Most importantly, the currently used microarray would have detected only 30 of the 81 different mutations that we found, of which 39 (48%) were novel. Conclusions: Based on these results, complete exon sequencing of the currently known USH genes stands as a definite improvement for molecular diagnosis of this disease, which is of utmost importance in the perspective of gene therapy.
- 11 May 2011
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 1-19
Open AccessComplete exon sequencing of all known Usher syndrome genes greatly improves molecular diagnosis
Background: Usher syndrome (USH) combines sensorineural deafness with blindness. It is inherited in an autosomal recessive mode. Early diagnosis is critical for adapted educational and patient management choices, and for genetic counseling. To date, nine causative genes have been identified for the three clinical subtypes (USH1, USH2 and USH3). Current diagnostic strategies make use of a genotyping microarray that is based on the previously reported mutations. The purpose of this study was to design a more accurate molecular diagnosis tool. Methods: We sequenced the 366 coding exons and flanking regions of the nine known USH genes, in 54 USH patients (27 USH1, 21 USH2 and 6 USH3). Results: Biallelic mutations were detected in 39 patients (72%) and monoallelic mutations in an additional 10 patients (18.5%). In addition to biallelic mutations in one of the USH genes, presumably pathogenic mutations in another USH gene were detected in seven patients (13%), and another patient carried monoallelic mutations in three different USH genes. Notably, none of the USH3 patients carried detectable mutations in the only known USH3 gene, whereas they all carried mutations in USH2 genes. Most importantly, the currently used microarray would have detected only 30 of the 81 different mutations that we found, of which 39 (48%) were novel. Conclusions: Based on these results, complete exon sequencing of the currently known USH genes stands as a definite improvement for molecular diagnosis of this disease, which is of utmost importance in the perspective of gene therapy.
- 11 May 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (6) , 1510-1514
Fourth case of cerebral, ocular, dental, auricular, skeletal syndrome (CODAS), description of new features and molecular analysis
Cerebral, ocular, dental, auricular, skeletal syndrome (CODAS, OMIM 600373) is a very rare congenital malformation syndrome. This clinical entity is highly distinctive and associates mental retardation, cataract, enamel abnormalities, malformations of the helix, epiphyseal and vertebral malformations, and characteristic dysmorphic features. Since 1991, only three affected children have been reported. The etiology and pattern of inheritance of CODAS syndrome still remain unknown. We describe a new sporadic case presenting with all the characteristic features of CODAS syndrome associated with previously unreported malformations of the heart, larynx, and liver. All investigations such as karyotype, metabolic screening and array CGH were normal.
- 11 May 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (6) , 1510-1514
Fourth case of cerebral, ocular, dental, auricular, skeletal syndrome (CODAS), description of new features and molecular analysis
Cerebral, ocular, dental, auricular, skeletal syndrome (CODAS, OMIM 600373) is a very rare congenital malformation syndrome. This clinical entity is highly distinctive and associates mental retardation, cataract, enamel abnormalities, malformations of the helix, epiphyseal and vertebral malformations, and characteristic dysmorphic features. Since 1991, only three affected children have been reported. The etiology and pattern of inheritance of CODAS syndrome still remain unknown. We describe a new sporadic case presenting with all the characteristic features of CODAS syndrome associated with previously unreported malformations of the heart, larynx, and liver. All investigations such as karyotype, metabolic screening and array CGH were normal.
- 20 November 2009
- Published by Wiley in Clinical Genetics
- Vol. 76 (6) , 558-563
Phenotype and genotype in females with POU3F4 mutations
X‐linked deafness is a rare cause of hereditary isolated hearing impairment estimated as at least 1% or 2% of the non‐syndromic hearing loss. To date, four loci for DFN have been identified and only one gene, POU3F4 responsible for DFN3, has been cloned. In males, DFN3 is characterized by a progressive deafness associated with perilymphatic gusher at stapes surgery and with a characteristic inner ear malformation. The phenotype of eight independent females carrying POU3F4 anomalies is defined, and a late‐onset hearing loss is found in three patients. Only one has an inner ear malformation. No genotype/phenotype correlation is identified.
- 20 November 2009
- Published by Wiley in Clinical Genetics
- Vol. 76 (6) , 558-563
Phenotype and genotype in females with POU3F4 mutations
X‐linked deafness is a rare cause of hereditary isolated hearing impairment estimated as at least 1% or 2% of the non‐syndromic hearing loss. To date, four loci for DFN have been identified and only one gene, POU3F4 responsible for DFN3, has been cloned. In males, DFN3 is characterized by a progressive deafness associated with perilymphatic gusher at stapes surgery and with a characteristic inner ear malformation. The phenotype of eight independent females carrying POU3F4 anomalies is defined, and a late‐onset hearing loss is found in three patients. Only one has an inner ear malformation. No genotype/phenotype correlation is identified.
- 20 May 2009
- Vol. 59 (5) , 630-1
[Genetic deafness in adults].
- 1 February 2008
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 146A (5) , 661-664
Perrault syndrome: Report of four new cases, review and exclusion of candidate genes
We report on two sporadic and two familial new cases with sensorineural hearing impairment and ovarian dysgenesis which are the cardinal signs of Perrault syndrome in females. Only one of them has a nervous system defect. We reviewed all the published cases of Perrault syndrome in order to define the clinical variability and to evaluate the frequency of the neurological anomalies in this clinical entity. Moreover we excluded GJB2, POLG, and FOXL2 as candidate genes in Perrault syndrome.
- 1 February 2008
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 146A (5) , 661-664
Perrault syndrome: Report of four new cases, review and exclusion of candidate genes
We report on two sporadic and two familial new cases with sensorineural hearing impairment and ovarian dysgenesis which are the cardinal signs of Perrault syndrome in females. Only one of them has a nervous system defect. We reviewed all the published cases of Perrault syndrome in order to define the clinical variability and to evaluate the frequency of the neurological anomalies in this clinical entity. Moreover we excluded GJB2, POLG, and FOXL2 as candidate genes in Perrault syndrome.